A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...
DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...
Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...
Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...
GR-0621 targets natural killer T cells, reducing inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF). The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results